HUTCHMED (China) Limited (H7T1) - Net Assets
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has net assets worth €1.25 Billion EUR (≈ $1.46 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.75 Billion ≈ $2.05 Billion USD) and total liabilities (€501.83 Million ≈ $586.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HUTCHMED (China) Limited asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.25 Billion |
| % of Total Assets | 71.37% |
| Annual Growth Rate | 22.33% |
| 5-Year Change | 20.37% |
| 10-Year Change | N/A |
| Growth Volatility | 56.98 |
HUTCHMED (China) Limited - Net Assets Trend (2016–2025)
This chart illustrates how HUTCHMED (China) Limited's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of HUTCHMED (China) Limited to evaluate the tangible quality of the company's equity base.
Annual Net Assets for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual net assets of HUTCHMED (China) Limited from 2016 to 2025. For live valuation and market cap data, see market value of HUTCHMED (China) Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.25 Billion ≈ $1.46 Billion |
+62.11% |
| 2024-12-31 | €771.85 Million ≈ $902.38 Million |
+3.83% |
| 2023-12-31 | €743.39 Million ≈ $869.10 Million |
+16.73% |
| 2022-12-31 | €636.87 Million ≈ $744.57 Million |
-38.73% |
| 2021-12-31 | €1.04 Billion ≈ $1.22 Billion |
+100.31% |
| 2020-12-31 | €518.95 Million ≈ $606.71 Million |
+65.85% |
| 2019-12-31 | €312.90 Million ≈ $365.82 Million |
-24.10% |
| 2018-12-31 | €412.25 Million ≈ $481.97 Million |
-14.99% |
| 2017-12-31 | €484.97 Million ≈ $566.98 Million |
+137.66% |
| 2016-12-31 | €204.06 Million ≈ $238.57 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HUTCHMED (China) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29828600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.62 Billion | 130.59% |
| Total Equity | €1.24 Billion | 100.00% |
HUTCHMED (China) Limited Competitors by Market Cap
The table below lists competitors of HUTCHMED (China) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mercuries Life Insurance Co Ltd
TW:2867
|
$1.84 Billion |
|
Visual China Group Co Ltd
SHE:000681
|
$1.84 Billion |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
$1.84 Billion |
|
Wedge Industrial Co Ltd
SHE:000534
|
$1.84 Billion |
|
Iluka Resources Ltd
AU:ILU
|
$1.84 Billion |
|
China TransInfo Technology Co Ltd
SHE:002373
|
$1.84 Billion |
|
RLX Technology Inc
NYSE:RLX
|
$1.84 Billion |
|
Burkhalter Holding AG
SW:BRKN
|
$1.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HUTCHMED (China) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 759,929,000 to 1,237,926,000, a change of 477,997,000 (62.9%).
- Net income of 456,909,000 contributed positively to equity growth.
- New share issuances of 1,578,000 increased equity.
- Other factors increased equity by 19,510,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €456.91 Million | +36.91% |
| Share Issuances | €1.58 Million | +0.13% |
| Other Changes | €19.51 Million | +1.58% |
| Total Change | €- | 62.90% |
Book Value vs Market Value Analysis
This analysis compares HUTCHMED (China) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.82x to 6.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.69 | €9.60 | x |
| 2018-12-31 | €0.58 | €9.60 | x |
| 2019-12-31 | €0.43 | €9.60 | x |
| 2020-12-31 | €0.67 | €9.60 | x |
| 2021-12-31 | €1.14 | €9.60 | x |
| 2022-12-31 | €0.71 | €9.60 | x |
| 2023-12-31 | €0.86 | €9.60 | x |
| 2024-12-31 | €0.89 | €9.60 | x |
| 2025-12-31 | €1.44 | €9.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HUTCHMED (China) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.91%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 83.30%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.42x
- Recent ROE (36.91%) is above the historical average (-10.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 6.35% | 5.41% | 0.63x | 1.86x | €-6.73 Million |
| 2017 | -5.79% | -11.08% | 0.40x | 1.29x | €-72.91 Million |
| 2018 | -19.23% | -34.94% | 0.40x | 1.37x | €-113.70 Million |
| 2019 | -36.81% | -51.75% | 0.44x | 1.61x | €-134.83 Million |
| 2020 | -25.97% | -55.15% | 0.31x | 1.50x | €-174.14 Million |
| 2021 | -19.72% | -54.66% | 0.26x | 1.39x | €-293.34 Million |
| 2022 | -59.12% | -84.62% | 0.41x | 1.69x | €-421.87 Million |
| 2023 | 13.80% | 12.03% | 0.65x | 1.75x | €27.73 Million |
| 2024 | 4.96% | 5.99% | 0.49x | 1.68x | €-38.26 Million |
| 2025 | 36.91% | 83.30% | 0.31x | 1.42x | €333.12 Million |
Industry Comparison
This section compares HUTCHMED (China) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,822,310,911
- Average return on equity (ROE) among peers: -30.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HUTCHMED (China) Limited (H7T1) | €1.25 Billion | 6.35% | 0.40x | $1.84 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $61.84 Billion | 5.45% | 0.94x | $1.16 Billion |
| PEPTONIC MEDICAL (28L) | $47.09 Million | -78.27% | 0.82x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $216.42 Million | -22.23% | 0.32x | $155.87 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $17.35 Million | -23.30% | 0.22x | $9.05 Million |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $62.07 Million |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more